Beijing Wantai Biological Pharmacy Enterprise Co Ltd - Asset Resilience Ratio
Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392) has an Asset Resilience Ratio of 11.64% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 603392 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Asset Resilience Ratio has changed over time. See Beijing Wantai Biological Pharmacy Enter (603392) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Beijing Wantai Biological Pharmacy Enterprise Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Beijing Wantai Biological Pharmacy Enter.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.60 Billion | 11.64% |
| Total Liquid Assets | CN¥1.60 Billion | 11.64% |
Asset Resilience Insights
- Moderate Liquidity: Beijing Wantai Biological Pharmacy Enterprise Co Ltd has 11.64% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Industry Peers by Asset Resilience Ratio
Compare Beijing Wantai Biological Pharmacy Enterprise Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Beijing Wantai Biological Pharmacy Enterprise Co Ltd (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Beijing Wantai Biological Pharmacy Enterprise Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.30% | CN¥1.45 Billion ≈ $211.76 Million |
CN¥14.04 Billion ≈ $2.06 Billion |
-6.78pp |
| 2024-12-31 | 17.09% | CN¥2.51 Billion ≈ $367.30 Million |
CN¥14.69 Billion ≈ $2.15 Billion |
+1.46pp |
| 2023-12-31 | 15.62% | CN¥2.46 Billion ≈ $359.30 Million |
CN¥15.71 Billion ≈ $2.30 Billion |
+3.25pp |
| 2022-12-31 | 12.38% | CN¥2.01 Billion ≈ $293.92 Million |
CN¥16.23 Billion ≈ $2.37 Billion |
+11.80pp |
| 2021-12-31 | 0.57% | CN¥40.39 Million ≈ $5.91 Million |
CN¥7.05 Billion ≈ $1.03 Billion |
-0.86pp |
| 2020-12-31 | 1.44% | CN¥50.36 Million ≈ $7.37 Million |
CN¥3.50 Billion ≈ $512.70 Million |
-1.24pp |
| 2019-12-31 | 2.68% | CN¥58.00 Million ≈ $8.49 Million |
CN¥2.16 Billion ≈ $316.80 Million |
+2.66pp |
| 2018-12-31 | 0.02% | CN¥343.70K ≈ $50.29K |
CN¥1.81 Billion ≈ $265.54 Million |
-0.02pp |
| 2017-12-31 | 0.04% | CN¥671.42K ≈ $98.25K |
CN¥1.66 Billion ≈ $242.29 Million |
0.00pp |
| 2016-12-31 | 0.04% | CN¥619.72K ≈ $90.68K |
CN¥1.45 Billion ≈ $212.83 Million |
+0.02pp |
| 2015-12-31 | 0.03% | CN¥301.31K ≈ $44.09K |
CN¥1.10 Billion ≈ $161.20 Million |
+0.02pp |
| 2014-12-31 | 0.01% | CN¥64.47K ≈ $9.43K |
CN¥805.50 Million ≈ $117.87 Million |
-0.01pp |
| 2013-12-31 | 0.02% | CN¥121.71K ≈ $17.81K |
CN¥606.98 Million ≈ $88.82 Million |
-- |
About Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, and sells biological diagnostic tests and vaccines in China and internationally. The company offers in vitro diagnostics and automated laboratory instruments, including Wan600, Wan BC2800, WanTLA immunoassay and biochemistry analyzers; chemiluminescence and biochemistry tests, including novel diagnostic tests fo… Read more